ERITROPOYETINA RECOMBINANTE PDF

Home  /   ERITROPOYETINA RECOMBINANTE PDF

Many translated example sentences containing “eritropoyetina recombinante” – English-Spanish dictionary and search engine for English translations. La farmacocinética de la eritropoyetina recombinante humana en pacientes con nefropatía endémica de los Balcanes. The Pharmacokinetics of Recombinant. Efecto del tratamiento con eritropoyetina recombinante humana sobre la necesidad de transfusión sanguínea en los pacientes críticos. Effect of human.

Author: Shaktilkree Faetilar
Country: Comoros
Language: English (Spanish)
Genre: Photos
Published (Last): 25 April 2018
Pages: 10
PDF File Size: 20.97 Mb
ePub File Size: 12.95 Mb
ISBN: 912-8-68950-815-5
Downloads: 28401
Price: Free* [*Free Regsitration Required]
Uploader: Miran

Results The study involved 24 hemodialysis patients, 10 patients with BEN and 14 with other kidney diseases, selected from 96 patients 40 BEN and 56 others who met the inclusion criteria.

The authors declare that they have no conflicts of interest related to the contents of this article. The last beta-Epo dose prior to pharmacokinetics blood samplingwas omitted in all patients but recontinued at the first hemodialysis session after the study with the dose used before. SRJ is a prestige metric based on the idea that not all citations are the same. On the other hand, residual renal function was maintained longer in BEN patients than in those with other kidney diseases 34 and our BEN patients were shorter on hemodialysis treatment than non-BEN patients.

The journal accepts submissions of articles in English and in Spanish languages.

Eritropoyetina recombinante humana en la insuficiencia renal crónica

This finding needs to be confirmed in a well-controlled study with a larger sample size. Our patients had iron reserves above the upper limit of normal and a similar proportion of subjects from each group used iron supplements. Continuing navigation will be considered as acceptance of this use. Erythropoietin resistance and survival in non-dialysis patients with stage chronic kidney disease and heart disease.

We recently showed that BEN hemodialysis patients required a higher dose of recombinant human erythropoietin for maintaining the target hemoglobin level than patients with other kidney diseases. The pharmacokinetic parameters of Epo are presented in Table 3. The significance of differences between mean values for groups was calculated using the Mann-Whitney U test and Student’s t-test. A number of factors may contribute to insufficient hematopoietic response to ESAs: The utilization of rHuEp changed definitively the treatment and the natural history of anemia in patients with chronic renal insufficiency CRIand now is modifying the treatment of anemia of other non-renal patients as anemia of premature, anemia in onco-hematological illnesses, anemia in human immunodeficiency virus HIV infection, and for reduction of allogenic blood transfusions in surgery.

  EPA 7196A PDF

CiteScore measures average citations received per document published. In addition, none of the mentioned factors for Epo hyporesponsiveness were significantly more pronounced in BEN than in non-BEN patients, except for older age. Subscribe to free Drugs.

Endemic Balkan Nephropathy, Proc. Investigation of the effects of altered receptor binding activity on the clearance of erythropoiesis-stimulating proteins: The eritrropoyetina study was initiated from earlier data involving BEN and 94 non-BEN patients, which showed that significantly higher beta-Epo doses for reaching and maintaining target hemoglobin level were necessary in BEN than in non-BEN patients.

Eritropoyetina Humana Recombinante Delta

The relevant pharmacokinetic parameters were calculated after noncompartmental pharmacokinetic analysis using Kinetica software Thermo Scientific, ver. SNIP measures contextual citation impact by wighting citations based on the total number of citations in a subject field. J Biol Chem ; Ciba Foundation Study Group No. Cellular trafficking and degradation of erythropoietin and novel erythropoiesis stimulating protein NESP. Universidad de Santiago de Compostela.

Population pharmacokinetics of darbepoetin alfa in peritoneal dialysis and non-dialysis patients with chronic kidney disease after single subcutaneous administration.

Population pharmacokinetics of darbepoetin alfa in healthy subjects. Srp arh cel lek ; Balkan endemic nephropathy, Human recombinant erythropoietin, Pharmacokinetics. Although an impact of age on Epo elimination in our patients cannot be fully excluded, neither age nor other covariates that differed between the groups was found affect Epo elimination in the ANCOVA model. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you.

  ENFERMEDAD DE CASTLEMAN PDF

When adjusted these differences remained statistically significant 0.

Statistics

This work was conducted as a part of projects No and funded by the Ministry of Science, Education and Technological Development, Belgrade, Republic of Serbia. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients.

The aim of this study was to compare the pharmacokinetics of beta-erythropoietin beta-Epo given subcutaneously to BEN patients and patients with other kidney diseases non-BEN and to evaluate the factors influencing beta-Epo kinetics.

Complexo Hospitalario Universitario Juan Canalejo. Delayed massive cerebral fat embolism secondary to severe polytrauma. To improve our services and products, we use “cookies” own or third parties authorized to show advertising related to client preferences through the analyses of navigation customer behavior.

Eritropoyetina Humana Recombinante Delta –

Anaemia in Balkan endemic nephropathy. Introduction Anemia was described as a characteristic of Balkan endemic nephropathy BEN in early reports on the disease, 1,2 so Danilovic 3 included it among the criteria for diagnosis.

A number of pharmacokinetic studies of ESA have been published, but comparison between them is difficult due to numerous methodological differences. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances. Nonerythropoietin receptor-mediated pathways may play a major role.

It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional.